argenx (ARGX) news
Recent news
Argenx closes purchase of Forte BioSciences
Argenx SE has completed its acquisition of Forte Biosciences, Inc. for $77 per share in an all-cash tender offer, representing a total equity value of approximately $2.2 billion . The deal, announced in July 2026, was structured to allow a wholly owned subsidiary of argenx to acquire all…
AInvest Wire · 4d agoArgenx SE: Wells Fargo raises target price to $1415 from $1350
AInvest Wire · 5d agoArgenx: UBS raises target price to $1400 from $960
UBS has revised its price target for Argenx (ARGX) from $960 to $1,400, reflecting a significant increase of approximately 45.6% in the firm’s valuation outlook for the biopharmaceutical company. The adjustment follows a reassessment of Argenx’s clinical and commercial progress, particularly in the…
AInvest Wire · 5d agoArgenx: Deutsche Bank cuts to hold from buy
Deutsche Bank has downgraded Argenx (ARGX) from "Buy" to "Hold," citing valuation concerns amid 40% surge in stock price . The firm has maintained its price target of EUR 655, reflecting a disciplined approach to the company’s current valuation. Argenx, a Dutch biopharmaceutical company,…
AInvest Wire · 6d agoArgenx SE: Oppenheimer raises target price to $1100 from $1037
AInvest Wire · Aug 18, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.